LAUSR

Prostate cancer is one of the most prevalent cancer types in men worldwide. With the progression of the disease to independent stimulation by androgen hormones, it becomes more difficult to control its progress. In addition, several studies have shown that chronic inflammation is directly related to the onset and progression of this cancer. For many decades, conventional chemotherapeutic drugs have not made significant progress in the treatment of prostate cancer. However, the discovery of docetaxel yielded the first satisfactory responses of increased survival of patients. In addition, alternative therapies using biomolecules derived from secondary metabolites of natural products are promising in the search for new treatments. Despite the advances in the treatment of this disease in the last two decades, the results are still insufficient and conventional therapies do not present the expected results they once promised. Thus, a revision and (re)establishment of prostate cancer therapeutic strategies are necessary. In this review, we also approach suggested treatments for molecular biomarkers in advanced prostate cancer.